Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA

Bibliography

• Mitchell HS, Stephens E. Contraception choice for HIV positive women. Sex Transm Infect 2004;80(3):167-73
   PubMed Web of Science ®Google Scholar
• Brinkman K, Vrouenraets S, Kauffmann R, Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000;14(17):2801-2
   PubMed Web of Science ®Google Scholar
• Gerard Y, Maulin L, Yazdanpanah Y, Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000;14(17):2723-30
   PubMed Web of Science ®Google Scholar
• John M, Moore CB, James IR, Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15(6):717-23
   PubMed Web of Science ®Google Scholar
• Mokrzycki MH, Harris C, May H, Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000;30(1):198-200
   PubMed Web of Science ®Google Scholar
• Olano JP, Borucki MJ, Wen JW, Haque AK. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 1995;21(4):973-6
   PubMed Web of Science ®Google Scholar
• Shaer AJ, Rastegar A. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. A case report and review of the literature. Am J Nephrol 2000;20(4):332-8
   PubMed Web of Science ®Google Scholar
• Tantisiriwat W, Tebas P, Polish LB, Elevated lactate levels in hospitalized persons with HIV infection. AIDS Res Hum Retroviruses 2001;17(3):195-201
   PubMed Web of Science ®Google Scholar
• Walker UA. Clinical manifestations of mitochondrial toxicity. J HIV Ther 2001;6(1):17-21
   PubMedGoogle Scholar
• Anderson TD, Davidovich A, Feldman D, Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab Invest 1994;70(5):724-39
   PubMed Web of Science ®Google Scholar
• Chariot P, Bourokba N, Brivet F. Mitochondrial DNA and nucleoside toxicity. N Engl J Med 2002;347(3):216-8, author reply -8
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Pezeshkpour GH, Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322(16):1098-105
   PubMed Web of Science ®Google Scholar
• Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989;264(20):11934-7
   PubMed Web of Science ®Google Scholar
• Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991;39(5):625-8
   PubMed Web of Science ®Google Scholar
• Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22(6):685-708
   PubMed Web of Science ®Google Scholar
• Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001;276(26):23616-23
   PubMed Web of Science ®Google Scholar
• Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 2001;81(6):777-90
   PubMed Web of Science ®Google Scholar
• Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1(5):417-22
   PubMed Web of Science ®Google Scholar
• Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003;2(10):812-22
   PubMed Web of Science ®Google Scholar
• Copeland WC, Chen MS, Wang TS. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 1992;267(30):21459-64
   PubMed Web of Science ®Google Scholar
• Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994;74(2):344-8
   PubMed Web of Science ®Google Scholar
• Nickel W, Austermann S, Bialek G, Grosse F. Interactions of azidothymidine triphosphate with the cellular DNA polymerases alpha, delta, and epsilon and with DNA primase. J Biol Chem 1992;267(2):848-54
   PubMed Web of Science ®Google Scholar
• Cox S, Ruden U, Nagy K, Serum levels and catabolism of 3′-azido-3′-deoxythymidine in vivo measured using a specific radioimmunoassay. J Virol Methods 1990;30(1):89-98
   PubMed Web of Science ®Google Scholar
• Heidenreich O, Kruhoffer M, Grosse F, Eckstein F. Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3′-azidothymidine triphosphate. Eur J Biochem 1990;192(3):621-5
   PubMedGoogle Scholar
• Reardon JE, Miller WH. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′-triphosphate. J Biol Chem 1990;265(33):20302-7
   PubMed Web of Science ®Google Scholar
• Bialkowska A, Bialkowski K, Gerschenson M, Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido-3′-deoxythymidine (AZT). Carcinogenesis 2000;21(5):1059-62
   PubMed Web of Science ®Google Scholar
• de la Asuncion JG, del Olmo ML, Sastre J, AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 1998;102(1):4-9
   PubMed Web of Science ®Google Scholar
• Choi J, Liu RM, Kundu RK, Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J Biol Chem 2000;275(5):3693-8
   PubMed Web of Science ®Google Scholar
• Choi J, Opalenik SR, Wu W, Modulation of glutathione synthetic enzymes by acidic fibroblast growth factor. Arch Biochem Biophys 2000;375(1):201-9
   PubMed Web of Science ®Google Scholar
• Raidel SM, Haase C, Jansen NR, Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol Heart Circ Physiol 2002;282(5):H1672-8
   PubMed Web of Science ®Google Scholar
• Barrientos A, Casademont J, Cardellach F, Qualitative and quantitative changes in skeletal muscle mtDNA and expression of mitochondrial-encoded genes in the human aging process. Biochem Mol Med 1997;62(2):165-71
   PubMedGoogle Scholar
• Lee HC, Wei YH. Mitochondrial alterations, cellular response to oxidative stress and defective degradation of proteins in aging. Biogerontology 2001;2(4):231-44
   PubMed Web of Science ®Google Scholar
• Bartley PB, Westacott L, Boots RJ, Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy. AIDS 2001;15(3):419-20
   PubMed Web of Science ®Google Scholar
• Martin AM, Hammond E, Nolan D, Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet 2003;72(3):549-60
   PubMed Web of Science ®Google Scholar
• Walker UA, Venhoff N. Multiple mitochondrial DNA deletions and lactic acidosis in an HIV-infected patient under antiretroviral therapy. AIDS 2001;15(11):1449-50
   PubMed Web of Science ®Google Scholar
• Eriksson S, Kierdaszuk B, Munch-Petersen B, Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991;176(2):586-92
   PubMed Web of Science ®Google Scholar
• Eriksson S, Munch-Petersen B, Kierdaszuk B, Arner E. Expression and substrate specificities of human thymidine kinase 1, thymidine kinase 2 and deoxycytidine kinase. Adv Exp Med Biol 1991;309B:239-43
   PubMedGoogle Scholar
• McKee EE, Bentley AT, Hatch M, Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol 2004;4(2):155-67
   PubMedGoogle Scholar
• Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991;266(14):9032-8
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Cucoranu I, Murine cardiac mtDNA: effects of transgenic manipulation of nucleoside phosphorylation. Lab Invest 2009;89(2):122-30
   PubMed Web of Science ®Google Scholar
• Saada A, Shaag A, Mandel H, Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 2001;29(3):342-4
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Cucoranu I, Transgenic cardiac-targeted overexpression of human thymidylate kinase. Lab Invest 2010;90(3):383-90
   PubMed Web of Science ®Google Scholar
• Bourdais J, Biondi R, Sarfati S, Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase. J Biol Chem 1996;271(14):7887-90
   PubMed Web of Science ®Google Scholar
• Connolly KJ, Hammer SM. Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition. Antimicrob Agents Chemother 1992;36(3):509-20
   PubMed Web of Science ®Google Scholar
• Miller WH, Daluge SM, Garvey EP, Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J Biol Chem 1992;267(29):21220-4
   PubMed Web of Science ®Google Scholar
• Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38(12):2743-9
   PubMed Web of Science ®Google Scholar
• Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46(3):716-23
   PubMed Web of Science ®Google Scholar
• Parker WB, White EL, Shaddix SC, Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J Biol Chem 1991;266(3):1754-62
   PubMed Web of Science ®Google Scholar
• Wu Y, Li N, Zhang T, Mitochondrial DNA base excision repair and mitochondrial DNA mutation in human hepatic HuH-7 cells exposed to stavudine. Mutat Res 2009;664(1-2):28-38
   PubMed Web of Science ®Google Scholar
• Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001;20(4-7):641-8
   PubMed Web of Science ®Google Scholar
• Cihlar T, Ray AS, Laflamme G, Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007;12(2):267-72
   PubMed Web of Science ®Google Scholar
• Ray AS, Cihlar T, Robinson KL, Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50(10):3297-304
   PubMed Web of Science ®Google Scholar
• Chariot P, Drogou I, de Lacroix-Szmania I, Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999;30(1):156-60
   PubMed Web of Science ®Google Scholar
• McKenzie R, Fried MW, Sallie R, Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333(17):1099-105
   PubMed Web of Science ®Google Scholar
• Miller KD, Cameron M, Wood LV, Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000;133(3):192-6
   PubMed Web of Science ®Google Scholar
• Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003;36(8):1082-5
   PubMed Web of Science ®Google Scholar
• Lonergan JT, Behling C, Pfander H, Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31(1):162-6
   PubMed Web of Science ®Google Scholar
• Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993;7(3):379-85
   PubMed Web of Science ®Google Scholar
• Gaou I, Malliti M, Guimont MC, Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 2001;297(2):516-23
   PubMed Web of Science ®Google Scholar
• Casademont J, Barrientos A, Grau JM, The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain 1996;119(Pt 4):1357-64
   PubMedGoogle Scholar
• Grau JM, Masanes F, Pedrol E, Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Ann Neurol 1993;34(2):206-11
   PubMed Web of Science ®Google Scholar
• Manji H, Harrison MJ, Round JM, Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine. J Neurol 1993;240(8):479-88
   PubMed Web of Science ®Google Scholar
• Ojetti V, Gasbarrini A, Migneco A, Lamivudine-induced muscle mitochondrial toxicity. Dig Liver Dis 2002;34(5):384-5
   PubMedGoogle Scholar
• White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001;77(3):158-73
   PubMed Web of Science ®Google Scholar
• Simpson DM, Bender AN. Human immunodeficiency virus-associated myopathy: analysis of 11 patients. Ann Neurol 1988;24(1):79-84
   PubMed Web of Science ®Google Scholar
• Herskowitz A, Willoughby SB, Baughman KL, Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992;116(4):311-13
   PubMed Web of Science ®Google Scholar
• Lewis W, Grupp IL, Grupp G, Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000;80(2):187-97
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Green E, Absence of mitochondrial toxicity in hearts of transgenic mice treated with abacavir. Cardiovasc Toxicol 2010;10(2):146-51
   PubMed Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622):1417-26
   PubMed Web of Science ®Google Scholar
• Ziagen. NDA20-977/NDA 20-978. 2000
   Google Scholar
• Sanz E. Analyses of adverse reaction reports in the WHO database. WHO Signal 2005:1-8
   Google Scholar
• Ide T, Tsutsui H, Hayashidani S, Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001;88(5):529-35
   PubMed Web of Science ®Google Scholar
• Lewis W. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy. Antivir Ther 2005;10(Suppl 2):M13-27
   PubMedGoogle Scholar
• Nojiri H, Shimizu T, Funakoshi M, Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 2006;281(44):33789-801
   PubMed Web of Science ®Google Scholar
• Kalayjian RC. The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis 2010;17(1):59-71
   PubMed Web of Science ®Google Scholar
• Valle R, Haragsim L. Nephrotoxicity as a complication of antiretroviral therapy. Adv Chronic Kidney Dis 2006;13(3):314-19
   PubMed Web of Science ®Google Scholar
• Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol 2009;5(10):563-73
   PubMedGoogle Scholar
• Izzedine H, Hulot JS, Villard E, Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194(11):1481-91
   PubMed Web of Science ®Google Scholar
• Knupp CA, Hak LJ, Coakley DF, Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1996;60(5):535-42
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001;6(1):14-20
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001;81(11):1537-44
   PubMed Web of Science ®Google Scholar
• Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics 2009;10(4):623-37
   PubMed Web of Science ®Google Scholar
• Berger AR, Arezzo JC, Schaumburg HH, 2′,3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993;43(2):358-62
   PubMed Web of Science ®Google Scholar
• Browne MJ, Mayer KH, Chafee SB, 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993;167(1):21-9
   PubMed Web of Science ®Google Scholar
• Cupler EJ, Dalakas MC. Exacerbation of peripheral neuropathy by lamivudine. Lancet 1995;345(8947):460-1
   PubMed Web of Science ®Google Scholar
• Dubinsky RM, Yarchoan R, Dalakas M, Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerve 1989;12(10):856-60
   PubMed Web of Science ®Google Scholar
• Merigan TC, Skowron G, Bozzette SA, Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med 1989;110(3):189-94
   PubMed Web of Science ®Google Scholar
• Yarchoan R, Pluda JM, Thomas RV, Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336(8714):526-9
   PubMed Web of Science ®Google Scholar
• Tozzi V, Libertone R, Liuzzi G. HIV pharmacogenetics in clinical practice: recent achievements and future challenges. Curr HIV Res 2008;6(6):544-54
   PubMed Web of Science ®Google Scholar
• Pandolfo M. Iron metabolism and mitochondrial abnormalities in Friedreich ataxia. Blood Cells Mol Dis 2002;29(3):536-47; discussion 48-52
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352(1):48-62
   PubMed Web of Science ®Google Scholar
• Villarroya F, Domingo P, Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (Lond) 2007;31(12):1763-76
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ. Does antiretroviral therapy increase or decrease the risk of cardiovascular disease? Curr HIV/AIDS Rep 2010;7(2):92-8
   PubMedGoogle Scholar
• Jacotot E, Ravagnan L, Loeffler M, The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000;191(1):33-46
   PubMed Web of Science ®Google Scholar
• Nie Z, Phenix BN, Lum JJ, HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 2002;9(11):1172-84
   PubMed Web of Science ®Google Scholar
• Tedaldi EM, Baker RK, Moorman AC, Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;36(3):363-7
   PubMed Web of Science ®Google Scholar
• Bazzoli C, Jullien V, Le Tiec C, Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 2010;49(1):17-45
   PubMed Web of Science ®Google Scholar
• Negredo E, Miro O, Rodriguez-Santiago B, Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009;49(6):892-900
   PubMed Web of Science ®Google Scholar
• Effros RB, Fletcher CV, Gebo K, Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008;47(4):542-53
   PubMed Web of Science ®Google Scholar
• Loeb LA, Wallace DC, Martin GM. The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. Proc Natl Acad Sci USA 2005;102(52):18769-70
   PubMed Web of Science ®Google Scholar
• Onen NF, Overton ET, Seyfried W, Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010;11(2):100-9
   PubMed Web of Science ®Google Scholar
• Bogner JR, Vielhauer V, Beckmann RA, Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001;27(3):237-44
   PubMed Web of Science ®Google Scholar
• Emtriva. NDA 021500/NDA 021896. 2008
   Google Scholar
• Epivir. NDA 020564/NDA 020596. 2008
   Google Scholar
• Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol 2010;6(1):105-14
   PubMed Web of Science ®Google Scholar
• Vidal F, Domingo JC, Guallar J, In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006;50(11):3824-32
   PubMed Web of Science ®Google Scholar